Guardant Health, Inc. (GH) stock
Close on Nov 11, 2026Market cap $20.77BP/E –Yield –
Guardant Health, Inc. grew revenue 41.7% to $1.28B over the twelve months to Sep 30, 2026. Free cash flow was -$232.15M. At the latest close the market valued the company at $20.77B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $20.77B
- P/E ratio
- –
- Price to sales
- 16.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1.12%
Fundamentals
- Revenue
- $1.28B
- Net income
- -$485.07M
- EPS, diluted
- -$3.68
- Free cash flow
- -$232.15M
- Book value per share
- -$2.05
- Diluted shares
- 134M
Trading
- Next earnings
- Feb 18, 2027 (estimated, after the close)
- Previous close
- $155.35
- Open
- $157.11
- Day's range
- $153.41 – $163.39
- Volume
- 1,524,801
- Average volume (20 days)
- 2,210,531
- Index membership
- Russell 1000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.63
- 52-week range
- $74.55 – $191.05
- RSI (14 days)
- 40.9
- Volatility (1 year)
- 52.9%
- Relative volume
- 0.74×
- WACC
- 13.0%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GH | S&P 500 | Difference | GH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.6% | -2.4% | −5.2 pts | ||
| 3 months | -6.2% | -1.2% | −5.1 pts | ||
| Year to date | +51.5% | +12.3% | +39.2 pts | ||
| 1 year | +58.4% | +12.4% | +46.0 pts | ||
| 3 years | +617.2% | +78.8% | +538.4 pts | +92.9% | +21.4% |
| 5 years | +47.0% | +75.2% | −28.1 pts | +8.0% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Guardant Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
About Guardant Health
Services-Medical Laboratories
Guardant Health is a precision oncology company that develops blood- and tissue-based tests, real-world data platforms, and artificial intelligence analytics across the cancer care continuum. The company's diagnostic offerings span early screening, minimal residual disease detection, recurrence monitoring, and therapy selection for advanced-stage cancer. Core products include the Shield blood test for colorectal cancer screening, Guardant Reveal for recurrence monitoring, and the Guardant360 portfolio of liquid and tissue biopsy assays for genomic profiling. In addition, it provides research platforms such as GuardantINFINITY, GuardantOMNI, GuardantINFORM, and GuardantConnect. Customers comprise community and academic oncologists, primary care clinicians, cancer centers, health systems, and biopharmaceutical companies.
Company profile, executives and historyGuardant Health stock: common questions
What is Guardant Health's stock price?
GH closed at $154.78 on Nov 11, 2026, down 0.37% on the day. Over the past 52 weeks it traded between $74.55 and $191.05.
What is Guardant Health's market cap?
Guardant Health was worth $20.77B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GH's P/E ratio?
Guardant Health lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.68), so it has no meaningful P/E ratio.
How much revenue does Guardant Health make?
Guardant Health reported revenue of $1.28B for the twelve months to Sep 30, 2026, up 41.7% from a year earlier.
Does Guardant Health pay a dividend?
No. Guardant Health has not paid a cash dividend over the last twelve months.
When does Guardant Health report earnings next?
Guardant Health is expected to report Q4 FY2026 results on Feb 18, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GH stock performed over the past year?
Including dividends, GH returned +58.4% over the past year, against +12.4% for the S&P 500.
How many GH shares are sold short?
9M shares were sold short at the latest FINRA report, 7.16% of the float, or 5.4 days of average trading volume.
Who are Guardant Health's competitors?
Companies most similar to Guardant Health by business, industry and size include CAI, BNR, VCYT, NTRA, GRAL.
See a number that looks wrong?